Jordan T. Johnson

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

S. Lonial, P. Tassone, P. Neri, 2010, Blood.

Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients

Ann M. Stowe, L. Cowell, E. Meffre, 2016, Acta Neuropathologica.

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

J. Keats, P. Neri, P. Duggan, 2012 .

Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation

Mary E. Wilson, R. Vijay, P. Wilson, 2021, The Journal of experimental medicine.

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

A. Belch, P. Neri, A. Klimowicz, 2012 .